Over the past two decades, GLP-1 and its analogues have been widely studied as treatments for type-2 diabetes and obesity; however, the most common side effects, including nausea and vomiting, slow down the progress of research [51,52,53]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.